Barclays Boosts Cytokinetics Stock Price Forecast

Investment bank raises price target on biopharmaceutical company's shares

Apr. 6, 2026 at 2:28pm

Got story updates? Submit your updates here. ›

Barclays analysts have increased their price target for Cytokinetics (NASDAQ:CYTK) stock from $87 to $95, maintaining an 'overweight' rating on the biopharmaceutical company's shares. The new target represents a potential upside of 45.45% from the stock's previous close.

Why it matters

This positive forecast from a major investment bank could signal growing confidence in Cytokinetics' drug development pipeline and future growth prospects, potentially attracting more investor interest and capital to the company.

The details

In a research note issued on Monday, Barclays analysts boosted their price objective on Cytokinetics from $87.00 to $95.00 and reiterated an 'overweight' rating on the stock. The new target price suggests the analysts see significant potential upside for Cytokinetics' shares. Several other analysts have also issued positive reports on the stock in recent months, with Morgan Stanley setting a $90.00 price target and Truist Financial raising their target to $92.00.

  • Barclays issued the updated price target and rating on April 6, 2026.

The players

Barclays

A major global investment bank that provides financial services and research coverage for publicly traded companies.

Cytokinetics

A late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Cytokinetics' upcoming financial results and pipeline updates to see if the company can deliver on Barclays' positive forecast.

The takeaway

This bullish call from Barclays underscores the growing optimism around Cytokinetics' drug development efforts and the potential for its stock price to appreciate significantly in the coming months.